Avantor, INC 8-K filings

Avantor announced its second quarter 2026 financial results, reporting net sales of $1,692.3 million and adjusted EPS of $0.21, while increasing full-year guidance.

Avantor, Inc. subsidiary obtains new senior secured Euro-denominated term loans, refinancing existing debt with a slightly lower interest rate spread.

Avantor, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, advisory votes on executive compensation, and ratification of its independent auditor.

Avantor announced its first quarter 2026 financial results, reporting flat net sales and a decrease in net income, while reaffirming its full-year guidance.

Avantor, Inc. has appointed Ludovic Brellier as Executive Vice President of Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026.

Avantor announces the resignation of CFO R. Brent Jones, with Steven Eck named interim CFO, while reaffirming its fiscal 2026 financial guidance.

Avantor, Inc. announced the appointment of director Simon Dingemans to its Audit & Finance Committee, effective February 19, 2026.

Avantor, Inc. announced the appointment of Sanjeev Mehra to its Compensation & Human Resources Committee and Audit & Finance Committee, effective February 19, 2026.

Avantor, Inc. reported significant declines in net sales, net income, and EPS for both Q4 and full-year 2025, while initiating a 'Revival program' and realigning business segments.

Avantor, Inc. announced the election of Simon Dingemans to its Board of Directors, effective January 2, 2026, filling a vacancy left by Jonathan Peacock's resignation.

Avantor, Inc. announced the election of Sanjeev Mehra, co-founder of Periphas Capital and former Goldman Sachs partner, to its Board of Directors.

Avantor, Inc. announced the appointment of Mary Blenn as Executive Vice President and Chief Operating Officer, alongside amendments to previous filings regarding CEO education and board committee assignments.

Avantor, Inc. announced a significant net loss of $712 million for Q3 2025, driven by a $785 million goodwill impairment charge, alongside a 5% decrease in net sales.

Avantor Funding, Inc. has amended its Credit Agreement, securing new revolving credit and term loan facilities totaling $1.4 billion and €950 million, while terminating its A/R facility and redeeming senior notes.

Avantor, Inc. announced a planned leadership transition for its Board of Directors, with Jonathan Peacock stepping down as Chairman and Gregory L. Summe appointed as his successor.

Avantor, Inc. has appointed Gregory T. Lucier, a seasoned executive with over 30 years of experience in the life sciences and advanced technology industries, to its Board of Directors, effective October 3, 2025.

Avantor, Inc. announced the election of Emmanuel Ligner as a director, effective August 18, 2025, filling a vacant board seat.

Avantor, Inc. announced a 1% decrease in net sales and significant drops in net income and EPS for the second quarter of 2025, alongside the upcoming CEO transition.

Avantor, Inc. announced the appointment of Emmanuel Ligner as its new President and Chief Executive Officer, effective August 18, 2025, succeeding Michael Stubblefield.

Avantor, Inc. announces the adoption of a new executive severance policy and the grant of retention awards to its senior leaders.

Avantor, Inc. announces that CEO Michael Stubblefield will step down upon the appointment of a successor, with a transition agreement in place.

Avantor's Q1 2025 results show a sales decrease of 6%, but the company is increasing its cost transformation target to $400 million in gross run-rate savings by the end of 2027.

Avantor's Q4 2024 results show a slight net sales decrease but improved net income and adjusted EBITDA, with the bioprocessing platform demonstrating high-single-digit growth.

Avantor's Executive Vice President, Sales and Customer Excellence, Jim Bramwell, has announced his retirement, effective around June 30, 2025, after 30 years of service.

Avantor, Inc. has appointed Dame Louise Makin as an independent director to its Board, effective November 4, 2024.

Avantor's third quarter results show a slight decrease in net sales, but positive performance in bioprocessing and improved free cash flow.

Avantor's second quarter results show a slight decrease in net sales but improvements in profitability and cash flow, driven by cost transformation initiatives and bioprocessing revenue.

Avantor, Inc. announced that Frederic Vanderhaegen, Executive Vice President, Europe, will depart from the company on June 30, 2024.

Avantor has appointed Corey Walker as President of Laboratory Solutions, succeeding Randy Stone, who is departing the company.

Avantor, Inc. held its 2024 Annual Meeting where stockholders approved amendments to the company's certificate of incorporation, elected nine directors, and ratified the appointment of Deloitte & Touche LLP as the independent auditor.